Search

everythinglearnresearchcommunity

for

Search:↓

Upadacitinib improved multiple immune-related conditions in one patient.

Dacomitinib can cause nail and skin issues, but these can be managed without stopping the drug.

Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.

Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.

Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.

Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.

Upadacitinib may help treat difficult cases of systemic lupus erythematosus.

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

Upadacitinib cleared scalp alopecia areata in three patients and also improved atopic dermatitis with minimal side effects.

Ritlecitinib has common side effects like headache and acne, and unexpected ones like diabetes and thyroid issues.

Upadacitinib is effective and safe for treating severe alopecia areata in teens.

Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.

JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.

Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

The rash resolved after stopping ponatinib.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

The drug showed promise in treating renal cell carcinoma with manageable side effects.

New therapies for rare skin diseases show promise but need more research.

Scalp psoriasis inflammation is mainly caused by bacteria-related triggers.

Abrocitinib effectively treated severe atopic dermatitis and mild alopecia areata in a 12-year-old boy after dupilumab failed.

Upadacitinib may cause hair loss.

A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.

Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.